Cholestasis: Clinical Trials

16 trials for Cholestasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 terminated. 16 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 216Terminated 16
Phase 11Terminated 1

Follow Cholestasis: new trials by email Literature Review of Cholestasis trials Research Report on Cholestasis

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)
Volixibat, Placebo - Intrahepatic Cholestasis of Pregnancy
Phase 2TerminatedMirum Pharmaceuticals, Inc.42021-01-042024-08-06
Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC
Obeticholic acid, Bezafibrate 200 MG, OCA Placebo - Primary Biliary Cholangitis
Phase 2TerminatedIntercept Pharmaceuticals752019-10-022026-07-16
Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus
CR845 1.0 mg, Placebo - Cholestatic Pruritus
Phase 2TerminatedCara Therapeutics, Inc.142019-06-252023-07-03
A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA
Baricitinib, Placebo - Primary Biliary Cholangitis
Phase 2TerminatedEli Lilly and Company22019-03-282020-10-14
Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis
BCD-085 - Liver Cirrhosis, Biliary
Phase 2TerminatedBiocad92018-04-272019-10-11
Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis
APD334 - Primary Biliary Cholangitis
Phase 2TerminatedArena Pharmaceuticals22017-12-292022-03-24
Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid
E6011, Placebo - Primary Biliary Cholangitis
Phase 2TerminatedEA Pharma Co., Ltd.292017-05-292019-01-04
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis
Cilofexor, Placebo to match cilofexor - Primary Biliary Cholangitis
Phase 2TerminatedGilead Sciences712016-12-012020-09-22
SMOFlipid to Lessen the Severity of Neonatal Cholestasis
SMOFlipid - Cholestasis, Jaundice, Obstructive
Phase 1 / Phase 2TerminatedUniversity of Florida22016-05-012017-04-17
Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)
Placebo Comparator, Experimental: Seladelpar 50 mg, Experimental: Seladelpar / MBX-8025 200 mg - Primary Biliary Cirrhosis (PBC)
Phase 2TerminatedGilead Sciences412015-11-042025-02-25
IBAT Inhibitor A4250 for Cholestatic Pruritus
A4250 - Biliary Cirrhosis, Primary
Phase 2TerminatedSahlgrenska University Hospital92015-01-012017-02-23
A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease
Omegaven - Cholestasis
Phase 2TerminatedUniversity of California, Los Angeles622009-08-012020-02-26
Compassionate Use of Omegaven IV Fat Emulsion
Omegaven - Cholestasis, Total Parenteral Nutrition-induced Cholestasis
Phase 2TerminatedCindy Haller152008-12-012017-03-10
Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)
INT-747, Ursodeoxycholic Acid (URSO), Placebo - Liver Cirrhosis, Biliary
Phase 2TerminatedIntercept Pharmaceuticals1652007-10-012024-02-06
SAMe to Treat Biliary Cirrhosis Symptoms
S-adenosyl-methionine (SAMe) capsules - Liver Cirrhosis, Biliary
Phase 2TerminatedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)502005-07-252017-07-02
Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody
NI-0801 - Primary Biliary Cirrhosis
Phase 2TerminatedLight Chain Bioscience - Novimmune SA2014-04-04

Narrower conditions

Liver Cirrhosis, Biliary (12)  ·  Pruritus (3)  ·  Fibrosis (2)  ·  Hyperphagia (2)  ·  Enterocolitis, Necrotizing (1)  ·  Fatigue (1)  ·  Intrahepatic Cholestasis of Pregnancy (1)  ·  Jaundice, Obstructive (1)  ·  Liver Diseases (1)

Broader conditions

Bile Duct Diseases (16)  ·  Biliary Tract Diseases (16)  ·  Digestive System Diseases (16)  ·  Pathological Conditions, Signs and Symptoms (15)  ·  Pathologic Processes (13)  ·  Cholestasis, Intrahepatic (12)  ·  Liver Cirrhosis (12)  ·  Liver Diseases (11)  ·  Fibrosis (10)  ·  Signs and Symptoms (5)  ·  Skin Manifestations (4)  ·  Skin Diseases (3)  ·  Skin and Connective Tissue Diseases (3)  ·  Signs and Symptoms, Digestive (2)

Interventions

fish oil triglycerides (2)  ·  obeticholic acid (2)  ·  (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1)  ·  Bezafibrate (1)  ·  Capsules (1)  ·  Parenteral Nutrition (1)  ·  S-Adenosylmethionine (1)  ·  SMOFlipid (1)  ·  Ursodeoxycholic Acid (1)  ·  baricitinib (1)  ·  cilofexor (1)  ·  difelikefalin (1)  ·  etrasimod (1)  ·  quetmolimab (1)  ·  volixibat (1)

Sponsors

Gilead Sciences (2)  ·  Intercept Pharmaceuticals (2)  ·  Arena Pharmaceuticals (1)  ·  Biocad (1)  ·  Cara Therapeutics, Inc. (1)  ·  Cindy Haller (1)  ·  EA Pharma Co., Ltd. (1)  ·  Eli Lilly and Company (1)  ·  Light Chain Bioscience - Novimmune SA (1)  ·  Mirum Pharmaceuticals, Inc. (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  Sahlgrenska University Hospital (1)  ·  University of California, Los Angeles (1)  ·  University of Florida (1)

Countries

United States (11)  ·  United Kingdom (6)  ·  Canada (3)  ·  Germany (3)  ·  Australia (2)  ·  Austria (2)  ·  France (2)  ·  Netherlands (2)  ·  New Zealand (2)  ·  Poland (2)  ·  Spain (2)  ·  Belgium (1)  ·  Croatia (1)  ·  Czechia (1)  ·  Estonia (1)

Top investigators

Arena CT.gov Administrator (1)  ·  Cindy Haller, MD (1)  ·  David A Shapiro, MD (1)  ·  Hanns-Ulrich Marschall, MD (1)  ·  Josef Neu, MD (1)  ·  Kara L Calkins, MD (1)  ·  Lynda Szczech (1)  ·  Marina Maevskaya (1)  ·  Pol F Boudes, M.D. (1)

Results publications

PMID 23894176, PMID 25500425, PMID 25543678, PMID 28521607, PMID 28818518, PMID 30411372, PMID 30900274, PMID 32072161, PMID 41603551

NIH funding

2015 (1), 2016 (1)